CJC-1295 No DAC: Mechanism of Action in Research Models

The CJC-1295 No DAC mechanism of action is studied through the GHRH receptor on pituitary somatotroph cells. CJC-1295 No DAC, also called modified GRF (1-29), is a synthetic 29-amino-acid analog of growth hormone-releasing hormone that carries stabilizing substitutions but omits the Drug Affinity Complex. The mechanisms below reflect biochemical assays, cell-culture studies, and animal models, and should be read strictly in a research context.

The CJC-1295 No DAC Mechanism of Action in Research Models

As an analog of the biologically active GHRH (1-29) fragment, CJC-1295 No DAC is investigated as a GHRH-receptor agonist and used as a model for studying the somatotropic axis. Its value as a research tool lies in isolating GHRH-receptor pharmacology in a form that is more enzymatically stable than native GHRH yet still short-acting, because it lacks the albumin-binding group of the DAC variant. This combination of properties is difficult to obtain from the native peptide, which is why the modified analog has become a standard tool for time-resolved receptor studies.

With a confirmed formula of C152H252N44O42, CAS 863288-34-0, and a molecular weight near 3367.9 g/mol, the compound is well defined chemically, which supports reproducible study design across laboratories. Registry-confirmed parameters allow concentration and molar calculations to be standardized, so that a stimulus described in one laboratory can be reproduced faithfully in another.

GHRH-Receptor Engagement

In experimental systems, engagement of the GHRH receptor is associated with cAMP-dependent signaling in somatotroph cells and the initiation of pulsatile growth hormone release. CJC-1295 No DAC is investigated for this interaction as a representative GHRH (1-29) analog, providing a defined stimulus for probing the receptor and its downstream cascade. The receptor is a class B G-protein-coupled receptor, and its activation through the cAMP/PKA axis is the canonical entry point for the somatotroph signaling that these studies characterize.

This cAMP/PKA-associated pathway is the same axis engaged by native GHRH and by related analogs such as sermorelin, which is why the compound is used to build directly comparable receptor-signaling datasets. Because the analog is chemically defined and enzymatically more stable, it delivers a cleaner and more reproducible stimulus than the native peptide, reducing one source of variability in mechanistic work.

Structural Stability and Short Duration

The substitutions distinguishing modified GRF (1-29) from native GHRH are studied for their role in reducing susceptibility to dipeptidyl-peptidase cleavage, which extends in-vitro stability relative to the native peptide. Because this variant lacks the albumin-binding DAC group, its circulating persistence is short compared with the DAC form. The result is a molecule that resists rapid enzymatic breakdown yet does not linger, which is exactly the profile needed to model discrete signaling events.

• Tetrasubstituted GRF (1-29) backbone studied for dipeptidyl-peptidase resistance.
• No Drug Affinity Complex, so no albumin conjugation and no extended half-life.
• Short, time-resolved receptor engagement suited to pulsatile-signaling studies.

This shorter duration is a deliberate research feature rather than a limitation, letting investigators model time-resolved receptor signaling. Where a long-acting analog produces sustained occupancy, the No-DAC form allows a stimulus to be applied, observed, and cleared, which is essential for studying recovery kinetics and repeated-pulse behavior.

Short-Acting Versus Long-Acting GHRH Analogs

The No-DAC form is frequently studied alongside its long-acting counterpart to contrast pulsatile and sustained GHRH-receptor stimulation within one framework. The complementary sustained-signaling profile is detailed in the CJC-1295 With DAC mechanism of action, and comparing the two clarifies how albumin binding reshapes signaling duration. Running both forms in the same model isolates duration as the experimental variable while holding receptor identity constant.

This paired design is one of the clearest ways to study how the temporal profile of a stimulus, rather than its identity, shapes downstream signaling. It turns a pharmacological difference into a controlled variable and is a recurring motif in somatotropic-axis research.

Convergent Signaling With GHS-Receptor Agonists

Because CJC-1295 No DAC engages the GHRH receptor while ghrelin/GHS agonists engage a separate receptor, the two are often paired in convergent-signaling research. The complementary phospholipase-C-coupled pathway is described in the Ipamorelin mechanism of action. This dual-pathway logic is the basis of the co-formulated blend and is applied further in the CJC-1295 No DAC research applications.

The two receptors converge on the same somatotroph population through distinct second-messenger systems, which makes their combination a natural subject for studies of signaling integration. Isolating the GHRH arm with the No-DAC analog is the first step in attributing any combined effect to convergence rather than to either pathway alone.

Interpreting Mechanistic Data

Present understanding derives from in-vitro assays, animal models, and human research on related GHRH analogs. Findings should be treated as observations within their experimental context, not as established clinical outcomes. The strength of the No-DAC form as a tool is that its defined chemistry and short duration make its stimulus reproducible, but conclusions still belong to the model in which they were generated.

Stable, well-characterized material is what allows the short-duration signal these studies depend on to be read cleanly.

Enzymatic Stability and the Modified Backbone

The stabilizing substitutions that define modified GRF (1-29) are the mechanistic reason the analog behaves differently from native GHRH at the bench. Native GHRH is cleaved rapidly by dipeptidyl peptidase, which limits its usefulness as a defined stimulus because its effective concentration falls quickly and unpredictably. The tetrasubstituted backbone is studied for its resistance to this cleavage, giving the analog a more consistent presence in vitro without introducing the albumin binding that would extend it into the sustained regime.

This intermediate profile, more stable than native GHRH yet still short-acting, is precisely what makes the No-DAC form valuable for pulsatile-signaling work. It delivers a reproducible stimulus that begins and ends within a defined window, which is difficult to obtain from either the fragile native peptide or the long-acting DAC variant. Researchers can review formulation practice in the CJC-1295 No DAC handling guide and source material with a certificate of analysis on the CJC-1295 No DAC product page.

For research use only. CJC-1295 No DAC is an investigational research peptide and is not approved for human or veterinary use. All descriptions refer to preclinical and in vitro laboratory research.